Valeant Pharmaceuticals (VRX) Near Deal to Acquire Actavis (ACT) for Over $13B

April 26, 2013 7:28 PM EDT Send to a Friend
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is near a deal to acquire Actavis (NYSE: ACT) for more than $13 billion, according to late reports from the Wall Street Journal. If consummated it would be one of the largest health-care deals of the year.

The deal is being envisioned as an all-stock transaction but talks are still fragile and could break off, the Journal said.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot M&A, Mergers and Acquisitions, Rumors, Trader Talk

Add Your Comment